MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/ejhf/xuag223

Медицинская библиотека · European journal of heart failure · 2026

Catheter ablation in end-stage heart failure with atrial fibrillation: an hierarchical endpoint analysis of the CASTLE-HTx trial.

Moersdorf Maximilian, Verbeeck Johan, Marrouche Nassir F, Costard-Jaeckle Angelika, Crijns Harry J G M, Bergau Leonard, Fox Henrik, Hindricks Gerhard, Dagres Nikolaos, Sossalla Samuel, Schramm Rene, Fink Thomas, Meynen Frederik, Sciacca Vanessa, Didenko Maxim, Konietschke Frank, Rudolph Volker, Gummert Jan, Tijssen Jan G P, Sommer Philipp, Sohns Christian

СтатьяПеревод в очереди

Аннотация

BACKGROUND

The CASTLE-HTx trial (NCT04649801) showed that the combination of catheter ablation and guideline-directed medical therapy (GDMT) was associated with a lower likelihood of a composite of death from any cause, implantation of a left-ventricular assist device (LVAD), or heart transplantation (HTx) in patients with end-stage heart failure (HF) and atrial fibrillation (AF).

AIMS: This is an ancillary analysis with the generalized pairwise comparison methodology of the main outcomes of CASTLE-HTx.

METHODS

In CASTLE-HTX, 194 patients were randomized to catheter ablation and GDMT (n = 97) or medical therapy alone (n = 97). The first hierarchical outcome was a composite of (1) death from any cause, (2) urgent HTx, (3) implantation of an LVAD, and (4) frequency of hospitalizations for worsening HF. Secondary analysis also included AF burden and left-ventricular ejection fraction improvement. Treatment effects are reported as net treatment benefit (NTB) and win odds, with corresponding confidence intervals (CIs).

RESULTS

Patients randomized to ablation had more wins with respect to death from any cause (28.4%/12.4%), HTx (4.3%/2.1%), LVAD implantation (4.2%/0.6%), and hospitalizations for worsening HF (24.8%/11.3%). 61.6% of pairs favoured ablation, 26.4% medical therapy, and 12.0% were tied. This resulted in a restricted NTB at 3 years of 35.3% (95% CI, 19.8-49.0, P < .001) favouring ablation (win odds: 2.09; 95% CI, 1.49-2.92). In the secondary analysis, 67.0% of pairs favoured ablation against 28.6% of pairs favouring medical therapy. The restricted NTB was 38.4% (95% CI, 22.8-52.0, P < .001) in favour of ablation (win odds: 2.25; 95% CI, 1.59-3.17).

CONCLUSIONS

This pairwise analysis of CASTLE-HTx confirms the clinical benefits of early catheter ablation in addition to GDMT among AF patients in end-stage HF. The treatment benefit was primarily driven by mortality and HF hospitalizations.

Для цитирования: Moersdorf Maximilian, Verbeeck Johan, Marrouche Nassir F, Costard-Jaeckle Angelika, Crijns Harry J G M, Bergau Leonard, Fox Henrik, Hindricks Gerhard, Dagres Nikolaos, Sossalla Samuel, Schramm Rene, Fink Thomas, Meynen Frederik, Sciacca Vanessa, Didenko Maxim, Konietschke Frank, Rudolph Volker, Gummert Jan, Tijssen Jan G P, Sommer Philipp, Sohns Christian. Catheter ablation in end-stage heart failure with atrial fibrillation: an hierarchical endpoint analysis of the CASTLE-HTx trial.. European journal of heart failure. 2026. DOI: 10.1093/ejhf/xuag223.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.